within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX27_Epcoritamab;
model Epcoritamab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX27;

  annotation(Documentation(
    info ="<html><body><p>Epcoritamab is a bispecific CD3xCD20 T-cell–engaging antibody indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other CD20-positive B-cell malignancies. It is administered subcutaneously and is approved for clinical use in several regions.</p><h4>Pharmacokinetics</h4><p>Population PK analysis in patients with B-cell non-Hodgkin lymphoma (DLBCL, FL, MCL) following subcutaneous administration.</p><h4>References</h4><ol><li><p>Hutchings, M, et al., &amp; Lugtenburg, PJ (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. <i>Lancet (London, England)</i> 398(10306) 1157–1169. DOI:<a href=&quot;https://doi.org/10.1016/S0140-6736(21)00889-8&quot;>10.1016/S0140-6736(21)00889-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34508654/&quot;>https://pubmed.ncbi.nlm.nih.gov/34508654</a></p></li><li><p>Li, T, et al., &amp; Xu, S (2025). Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. <i>Clinical pharmacokinetics</i> 64(1) 127–141. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01464-2&quot;>10.1007/s40262-024-01464-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39708278/&quot;>https://pubmed.ncbi.nlm.nih.gov/39708278</a></p></li><li><p>Takaura, K, et al., &amp; Ganoza, ER (2024). [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly. <i>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</i> 159(1) 61–68. DOI:<a href=&quot;https://doi.org/10.1254/fpj.23076&quot;>10.1254/fpj.23076</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38171842/&quot;>https://pubmed.ncbi.nlm.nih.gov/38171842</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Epcoritamab;
